Monitor the pace and pricing of share sales, as the at-the-market structure allows for opportunistic selling that could pressure the stock price. The offering follows a recent shelf registration, indicating potential for future dilution. The company's going concern warning in its financials adds risk to the capital raise strategy.
ONCY drugs
ONCY drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 7 $0.9000entry
- T+1 · 7mo ago +1.11%α −1.43% · $0.9100
- T+5 · 7mo ago +13.33%α +8.00% · $1.02
- T+20 · 7mo ago +3.33%α −6.45% · $0.9300
- T+60 · 5mo ago −0.10%α −13.37% · $0.8991
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Oncolytics Biotech is conducting an at-the-market offering of up to $75 million in common stock through Jefferies, following a $250 million shelf registration. The company plans to use the proceeds for clinical development of pelareorep and general corporate purposes. This offering follows a recent shelf registration and represents potential future dilution.
Key Facts
- Oncolytics Biotech is offering up to $75 million in common stock through an at-the-market offering with Jefferies
- The offering is part of a $250 million shelf registration filed on April 1, 2026
- Proceeds will fund clinical development of pelareorep, research and development, operating costs, and general corporate purposes
- The offering price is up to $0.96 per share, with an expected issuance of up to 78,125,000 shares
- Investors will experience immediate dilution of $0.59 per share
- The company has a market cap of $103 million and reported net tangible book value of $(3.8) million as of December 31, 2025
Financial Impact
Up to $75 million in gross proceeds with potential for significant dilution
Risk Factors
- Immediate dilution of $0.59 per share for new investors
- Potential for further dilution if the company issues additional shares
- The company's financial statements include an explanatory paragraph about conditions that raise substantial doubt about its ability to continue as a going concern
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001104659-26-039932 |
| Document: 0001104659-26-039932-index-headers.html | 0001104659-26-039932 |
| Document: 0001104659-26-039932-index.html | 0001104659-26-039932 |
| Document: 0001104659-26-039932.txt | 0001104659-26-039932 |
Track record
32 reports on ONCY
3 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +10.53% at T+5 after the Apr 6, 2026 report. 6 of 11 went positive at some point.
Filters
- Nov 13, 20263d ago Press Release Neutral 3/10 Entry $0.3700 Now $0.3400 −8.11% settles Dec 14
- Nov 12, 20264d ago 8-K Neutral 3/10 Entry $0.3720 Now $0.3400 −8.60% settles Dec 11
- Nov 11, 20265d ago Press Release Neutral 3/10 Entry $0.3720 Now $0.3400 −8.60% settles Dec 11
- Nov 9, 20267d ago 8-K Neutral 3/10 Entry $0.4077 Now $0.3400 −16.61% settles Dec 8
- Nov 9, 20267d ago Press Release Neutral 3/10 Entry $0.4077 Now $0.3400 −16.61% settles Dec 8
- Nov 4, 202612d ago 8-K Neutral 4/10 Entry $0.4248 Now $0.3400 −19.96% settles Dec 3
- Nov 4, 202612d ago Press Release Bullish 6/10 Entry $0.4248 Now $0.3400 −19.96% settles Dec 3
- Oct 27, 202620d ago 8-K Bullish 6/10 Entry $0.4623 Now $0.3400 −26.45% settles Nov 24
- Oct 27, 202620d ago Press Release Bullish 6/10 Entry $0.4623 Now $0.3400 −26.45% settles Nov 24
- Oct 20, 202627d ago 8-K Neutral 3/10 Entry $0.4986 Now $0.3400 −31.81% settles Nov 17
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers